Category Archives: LEDs

August 15, 2006 – Synova, a privately held Swiss developer of water jet-guided laser technology, has secured an additional $8.1 million (CHF 10 million) in funding from Swiss banks, to help fuel its push to create several micromachining centers in key high-tech regions around the world.

Synova claims to have more than 50 of its flagship MicroJet machines running in full production at 30 different customer sites, and is seeking to develop the localized centers to enable faster, more responsive support for customers. The funding will also allow the company to address other industries and applications for its technology.

The company’s “laser microjet” technology replaces traditional cutting technologies such as conventional lasers and diamond blade saws, for applications in inkjet print head MEMS, HDDs, and OLEDs to help prevent damaging the materials due to their thermo-mechanical stress sensitivity. Synova is positioning its water-driven laser vs. competitive techniques for high-speed slotting of silicon wafers to be diced into barrier chips for inkjet print heads, touting cutting times of 2.6 sec/slot and with no damage.

Last month Synova said it is preparing to open a micromachining center in Silicon Valley by early 2007, to tap into local growth markets including inkjet printer head MEMS, hard disk drive (HDD) and organic light emitting diodes (OLEDs). The company forecasts compound annual growth rates (CAGR) for inkjet printer head MEMS and HDDs at 8.8% through 2008 and 15.5% through 2009, while OLEDs are seen growing by 74% over the next year.

August 15, 2006 – Worldwide sales of semiconductor manufacturing equipment rose just a fraction in 2Q06 from the previous quarter, but a big push in orders suggests significant demand for new tools, according to new data from SEMI.

Overall, billings in 2Q06 were $9.58 billion, an increase of 0.2% from 1Q06, but up 27% from 2Q05. Bookings, meanwhile, showed much better gains, up 23% sequentially and about 60% higher than a year ago, to $11.53 billion. SEMI president Stanley Myers noted that 2Q06 billings were at the highest levels since 1Q01.

By geography, China and Rest-of-World regions led the way in growth both vs. the prior quarter and year-ago periods (83% and 15%, and 193% and 30%, respectively). Taiwan enjoyed 11% sales growth from 1Q06 to 2Q06, while both Korea and Japan declined sequentially. Year-on-year, every region showed positive growth, with most regions in a pack at around ~30% growth, led by North America and Rest-of-World.

Quarterly billings data (US $M)

Region……………2Q06……………vs. 1Q06……………vs. 2Q05

Japan…………………….$1924…………..$2331 (-17%)…………$1584 (21%)
North America…………..1836……………1795 (2%)………………1400 (31%)
Taiwan…………………….1763……………1589 (11%)…………….1619 (9%)
Korea………………………1518……………1774 (-14%)……………1241 (22%)
Europe………………………954……………..920 (4%)………………..799 (19%)
Rest of World………………907……………..788 (15%)………………696 (30%)
China………………………..693……………..380 (83%)………………236 (193%)
TOTAL……………………..9594……………9577 (0.2%)……………7576 (27%)

Source: SEMI, SEAJ

August 7, 2006 – Air Products has signed a deal to license, develop, and market products based on technology from the U. of Connecticut that aims to help increase the lifetime of polymer light-emitting diodes (P-OLED) for displays.

Focused on poly (thieno [3,4-b] thiophene), and dopant polymer technology from Air Products, the two groups have developed hole injection layer (HIL) materials for P-OLEDs that they claim provide a dramatic increase in display lifetime compared to conventional HIL materials. Air Products says P-OLEDs based on its HIL materials exhibit lifetime to half luminance up to 10x longer than conventional HIL materials based on competing thiophene polymers.

The two-layer architecture, which typically obviates the need for a costly protective interlayer, would help reduce process steps during display manufacturing, leading to higher device yields and reducing the need to purchase additional deposition tools.

“We believe that these patented materials will help to enable more rapid growth of the emerging OLED display industry,” stated John Dickenson, senior business development manager for Air Products.

August 3, 2006 – Worldwide sales of semiconductors slipped 0.9% in 2Q06 from the previous quarter, but were up 9% year-on-year, as the industry tries to balance strong unit demand with downward pressure on average selling prices (ASP).

Chip sales in June totaled $19.6 billion (representing a moving three-month average), vs. $19.78 billion in May, and $17.96 billion in June 2005. 2Q06 sales came in at $58.9 billion, a decrease of 0.3% from 1Q06 but up 9.4% from 2Q05. 1H06 sales totaled $118 billion, up 8.3% over 1H05 sales of about $108.95 billion, and down about 0.4% from 2H05 sales of $118.53 billion.

Sales in most geographic regions were flat or slightly up in June vs. the previous month, except for the Asia-Pacific region (-0.9%). Based on a three-month rolling average, all regions showed slight declines, led by North America (-5%). Year-on-year, both North America and Asia achieved double-digit growth in June (11.4% and 12.8%, respectively).

SIA president George Scalise noted the sales growth Y-Y, and stagnation M-M and Q-Q, reflects the current environment reported by chipmakers and suppliers over the past few weeks. While unit demand has remained strong, up about 5% across the industry during 2Q, strong competitive pressures have reduced prices in some major product sectors, impacting revenues. In a Webcast discussing the data, Scalise pointed to a noticeable dropoff in the microprocessor segment — sales sunk 18% from 1Q to 2Q, and were 12% lower than a year ago. The segment has been impacted by a significant price decline, reflecting an inventory correction and competitive pressures (read: Intel and AMD), he noted.

End market demand is still very strong, Scalise said — unit sales of PCs rose about 10% in 2Q over the same period a year ago. But pricing pressures are hurting here as well. During the same timeframe, the average price of a laptop fell by more than 18%, to an average of about $960, Scalise noted.

Communications applications remain strong, particularly for cell phones, which ended the quarter with 235 million unit shipments, and is expected to grow 4% in 3Q and “at least 10%” in 4Q, amounting to total growth of 20% in 2006, and nearly a billion units shipped by year’s end, Scalise noted. Digital TVs also are showing strong growth (~50% projected for the year), while MP3 players “are a little bit weaker, but not that much,” Scalise said.

Despite heightened geopolitical concerns, linked to oil and gas prices that continue to creep higher, Scalise nevertheless maintained optimism about keeping to the SIA’s 2006 forecast of 9.8% sales growth. “If there’s any impact from [rising energy prices], it’s minimal at this point,” he said.

Major product line summary, 2Q06
(Sales in US $B)

Product………………………2Q06…..vs. 1Q06 (% change)…..vs. 2Q05 (% change)

Discrete…………………….4.15……….3.85 (7.9)………….3.78 (9.9)
Optoelectronics…………..4.07……….3.91 (4.0)………….3.62 (12.6)
Analog………………………9.27……….7.66 (21.0)………..8.89 (4.2)
MOS Microprocessors……7.25……….8.27 (-12.2)……….8.84 (-18.0)
MOS Microcontrollers……3.19……….2.96 (7.6)………….2.98 (7.1)
MOS DSP…………………..2.11……….1.84 (14.7)………..2.04 (3.3)
MOS Logic………………..14.11……..13.62 (3.6)………..14.56 (-3.1)
MOS DRAM…………………7.44……….5.94 (25.3)………..6.65 (11.9)
NAND flash…………………2.63……….2.23 (18.0)………..3.04 (-13.5)
NOR flash…………………..2.17……….1.85 (17.3)………..2.03 (7.3)

Source: SIA, WSTS

Company sees commercialization in 2007

August 03, 2006 — /MARKET WIRE/ — LOS ANGELES, CA — Eugene Science, Inc. (OTCBB: EUSI), a developer and marketer of advanced nutraceutical products, today announced that the Korean Industrial Property Office has granted the Company a patent on its AD/ADD production process.

This brings to three the number of AD/ADD production patents granted to the Company in Korea. International patents have been applied for in the U.S., Japan and China. Additionally, China has granted the Company a patent on its AD/ADD microorganism catalyst, with patent applications pending in the U.S. and Japan.

AD/ADD is a steroid hormone intermediate and key ingredient for most steroid hormone medical products including synthetic estrogens, gestogens, gluco-corticoids, and mineral-corticoids — a market led by Pfizer and Schering-Plough and estimated at $7.5 billion worldwide. These products have been extensively used in treating arthritis, neuralgia, sterility as well as for contraception and hormone replacement therapy (HRT). Examples of such products include Testoviron(r), a testosterone injection manufactured by Schering-Plough, and Depo-subQ Provera 104(tm), an injectable contraceptive manufactured by Pfizer.

Eugene Science’s AD/ADD biotechnology — established at prototype scale — uses the Company’s patented microorganism-based process to produce far higher conversion rates of sterols into AD/ADD as compared with conventional chemical synthesis. It is also substantially more cost-effective and environmentally friendly. The Company’s research and development on AD/ADD production is being performed in collaboration with the Korea Research Institute of Bioscience and Biotechnology (KRIBB), Korea’s largest and leading biotechnology research center.

KRIBB has committed to work with Eugene Science to scale its AD/ADD biotechnology to one-ton production levels, which the Company intends to commercialize in 2007. The Korean Government is providing the project with financial support.

“This patent is another important milestone this year for Eugene Science as AD/ADD represents our next major product line,” said Seung Kwon Noh, Chief Executive Officer, Eugene Science. “The capital requirements to commercialize our AD/ADD production process are extremely modest, especially when compared to its large and growing market. Eugene Science has already met with leading AD/ADD pharmaceutical producers, and Eugene Science intends to begin to commercialize its AD/ADD technology through licensing or other strategic alliances in 2007.”

The Company’s AD/ADD biotechnology process is based on its patented plant sterol nanotechnology process which renders these sterols water soluble (the science behind its CholZero(tm), or CZ(tm), nutraceutical product line). Using these water soluble nano-sized sterol particles, the Company then applies its patented plant sterol fermentation and production process to produce AD/ADD.

“Our AD/ADD microbial conversion production process is vastly superior to existing conventional processes for efficiency and purity,” said Jang Hyun Cho, Ph.D., Eugene Science Director of Pharmaceutical Ingredient Development. “We use a simpler purification process, and enable wider substrate — or sterol conversion to AD/ADD — usages. This is only possible with Eugene Science’s patented nanotechnology for converting non-soluble sterols into water soluble sterols. Our technology also reduces the cost of production by broadening the otherwise limited spectrum of raw materials that can be used to produce AD/ADD, from sitosterol only, to all kinds of plant sterols.”

“With the successful grant of our patent in Korea, we can expect grants in other countries including the United States to follow shortly,” Dr. Cho concluded.

About Eugene Science

Based in Bucheon, Kyunggi-Do, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ(tm), is a patented, nanoscience-based, water-soluble functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ(tm) is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy. Please visit www.eugene21.com.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words “estimate,” “project,” “potential,” “intended,” “expect,” “anticipate,” “believe” and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management’s projections, estimates and expectations include, but are not limited to: changing economic influences in the neutraceutical industry; dependence on key personnel; actions of third parties; the market for and the research, development and commercialization of the AD/ADD process; and the availability of adequate financing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investor Relations:
Capital Group Communications
Richard Carpenter
Mark Bernhard
email: [email protected]
(415) 332-7200

SOURCE: Eugene Science, Inc.

July 27, 2006 – Toshiba Corp. has agreed to settle a dispute with an ex-engineer who was instrumental in the creation of flash memory, two years after he sued them for reimbursement for his work while at the company.

Under terms of the settlement, Fujio Masuoka will receive 87 million yen (about $745,000), a fraction of the 1 billion yen he had initially sought, but far exceeding the 6 million yen Toshiba originally gave him years ago in recognition of his invention’s contributions.

Masuoka, now a professor at Tohoku U., filed suit in early 2004 in Tokyo District Court seeking 1 billion yen ($9.2 million) from his former employer — down from his original demands of 8 billion yen (~$75 million) — for his contributions toward the creation of flash memory. It was among the first such lawsuits in Japan where a former employee sought reimbursement for technology developed while working at the employer. Masuoka claimed Toshiba had reaped tens of billions of yen (>$150 million) since the 1980s from transferals of patent rights to flash memory, which is now ubiquitous technology in digital consumer devices.

“The sum is not so satisfactory when compared with what I had demanded but, if I take into account that I had been given six million yen as the reward, it is a big step forward,” he said, quoted by various press reports. “The court has helped establish a reward system encouraging inventors… a growing number of Japanese companies have been highly rating engineers. Right treatment of engineers can help advance Japan’s industry.”

Also in 2004, the Japanese court handed out 20 billion yen (~$180 million) to Shuji Nakamura, who developed blue LED technology while working for Nichia in the 1990s. Nichia appealed, and Nakamura settled for 840 million yen (~$7 million) in early 2005. And a case filed against Hitachi Ltd. relating to optical disk technology is still pending.

July 21, 2006 – AmberWave Systems Corp., a Salem, NH-based developer of IP relating to strained silicon and other advanced materials, has closed an oversubscribed $25 million Series E round of funding, led by current investors Adams Capital Management, TeleSoft Partners, Arch Venture Partners, 3i, and The Hillman Co., bringing its total cash raised in five rounds to more than $91 million.

The company recently announced additional hiring to expand its research efforts and an expansion of agreements with leading universities — in March AmberWave and Purdue U. agreed to jointly develop technologies for integrating semiconductor devices on III-V materials.

July 20, 2006 – Price cuts and rising inventory dented Intel Corp.’s 2Q06 performance, and the company has responded by cutting its capital spending and R&D targets for the rest of the year.

For its 2Q06, Intel posted revenues of $8.01 billion, at the bottom end of its $8.0-$8.6 billion range projected in April, and down 10% from 1Q06 and 13% from 2Q05. Net income was just $885 million (including about $200 million in share-based compensation), vs. $1.34 billion in the prior quarter, and $2.04 billion a year ago. Gross margins came in at 52.1%, better than a midquarter expectation of 49%. In just the past six months, Intel has seen its sales drop more than 20%, and profits shrink by nearly 65%. Sales are at their lowest levels in two years, and the chipmaker’s profits fell below $1 billion for the first time since 2Q03, to a level not seen since the fall of 2002 — although it’s worth noting that share-based compensation wasn’t included prior to this year. “It’s clearly turning out to be somewhat of a train wreck,” said Eric Ross, analyst at ThinkEquity Partners, quoted by MarketWatch.

Lower-than expected-microprocessor average selling prices (ASPs) were to blame for the poor performance, as customers move to reduce processor inventory levels “in a highly competitive pricing environment,” the chipmaker stated. Only the company’s flash memory units showed growth during the quarter. Sales were down sequentially in every region vs. normal seasonal patterns.

During the conference call Q&A, Intel CEO Paul Otellini noted the inventory buildup has been due to in part to faster-than-expected qualification of 65nm products including Conroe, but cautioned against worries that Intel will find itself in a similar position it was in late 2004 and early 2005, where it had to burn off lots of inventory following excessive buildup. “The last time we built inventory, we jerked down factories, created shortages of chipsets, which affected our microprocessor business,” he said. “We don’t want to overreact to a one-quarter inventory build, particularly since we feel we built all the right stuff.”

Intel said its outlook for the next quarter is improving, projecting a 3%-11% increase in 3Q06 sales to a range of $8.3-$8.9 billion. Gross are still expected to be down a little bit, at 49% plus or minus a couple of points, compared with nearly 60% a year ago. But following the disappointing 2Q results, Intel cut its targets for full-year 2006 — capital spending (including spending on IM Flash, the Intel-Micron flash JV) is now budgeted at $6.0-$6.4 billion, down 6% from a range of $6.4-$6.8 billion projected three months ago. R&D expenditures also were lowered, to approximately $6.0 billion, vs. $6.1 billion estimated in 1Q06, while FY06 gross margins are now expected to come in at 51%, down from 53% expected last quarter. Intel execs wouldn’t give numerical estimates on FY06 revenue projections, which last quarter had been set at $38.8 billion (down 3% Y-Y), but stated that FY06 sales would “follow normal seasonal patterns.”

In the conference call Q&A, Intel execs noted that half the $400 million cutback in capital spending is due to a slowdown in construction spending, while the other half was due to the company finding efficiency improvements in its backend/test processes, with “ways to increase loadings into that equipment.” Capacity and utilization rates haven’t changed, the execs said, but the company does want to keep finding ways to better use the capacity it has — “we hope to find six more ways to save money.”

Intel also noted that it is beginning to see efficiencies out of its NOR flash division, several weeks after it broke out other flash-related manufacturing technology development work to be part of the NOR division. The unit posted a $149 million operating loss in 2Q and $253 million for 1H06, but the execs said those losses were due in part to startup costs and would be reduced, adding that next year NOR revenues might be “meaningful” as a percent of overall sales, vs. the current 6.7% level.

In response to sagging business, earlier this year Intel said it would closely examine all areas of the business, in an effort to maximize efficiencies, identify and eliminate redundancies and underperforming areas, and ultimately save $1 billion in costs. That effort already has resulted in the $600 million sale of its communications and applications processor business to Marvell Technology Group, and just last week the company said it would lay off 1000 managers, about 1% of its workforce.

Meanwhile, the Associated Press reports Intel has shuffled more top management ranks, starting with its mobility group, moving EVP Sean Maloney from co-manager of its mobility group to lead the sales and marketing group, and leaving SVP David Perlmutter to lead the mobility group on his own. Anand Chandrasekher, SVP and joint head of the sales team, will be moved to manage a new unit targeting “ultramobile PCs” (i.e., smaller than laptops but bigger than handheld devices), while counterpart Eric Kim will become GM of Intel’s digital home group, overseeing the Viiv PC platform and other A/V products. Don MacDonald, who formerly led the digital group, will become VP of corporate brands. In addition, two top executives announced their retirement: Bill Siu, GM of channel platforms, and Richard Wirt, co-GM of software solutions.

July 19, 2006 – Worldwide semiconductor companies spend more than $30 billion in 2005 on R&D, 10% more than the previous year, and slighly ahead of the 9% compound annual growth rate over the past five years, according to new data from analyst firm IC Insights Inc., Scottsdale, AZ. Meanwhile, the 30 largest fabless suppliers have pushed their R&D investments at double that rate since 2001.

Intel spent about $22.1 billion on R&D from 2001-2005, accounting for roughly a quarter of the top 25 IDMs during that period (i.e., those that manufacture products and break out their semiconductor financial results), and about $10 billion more than any other semiconductor company. However, as a percentage of sales, Intel’s R&D expenses were lower than the group, at 14% vs. 16% for the top 25 IC manufacturers, and compared with 17% of sales from the top 30 fabless suppliers, the analyst firm noted.

Among other top-25 IDMs, Samsung notably spent $12.0 billion on R&D, a full 20% of its five-year sales, as did Freescale Semiconductor ($5.2 billion). Infineon’s R&D investments amounted to 19% of its sales from 2001-2005 (about $6.3 billion), while Texas Instruments and STMicroelectronics both invested an amount equal to 17% of sales ($9.0 billion and $6.4 billion, respectively).

For the top 30 fabless suppliers, Broadcom led the way with an R&D budget amounting to 28% of sales ($2.4 billion), followed by Marvell (23%, $1.0 billion), Xilinx (19%, $1.3 billion), Qualcomm (15%, $3.1 billion), and Nvidia (14%, $1.3 billion).

IC Insights also noted that silicon foundries have consistently spent less of their sales on R&D over the past five years compared with IDMs and major fabless customers, mainly because they don’t develop their own products. During the 2001-2005 period, foundry leader Taiwan Semiconductor Manufacturing Co. (TSMC) invested a total of $1.8 billion, or 6% of sales, on R&D, while United Microelectronics Corp. (UMC) spent $1.1 billion (9.0% of sales), Chartered Semiconductor Manufacturing Ltd. in Singapore invested $539 million in R&D (14% of sales), and Semiconductor Manufacturing International Corp. (SMIC) in China invested $236 million (9.0% of sales).

July 19, 2006 – A new report by Andrew Maynard, chief science advisor for the Project on Emerging Nanotechnologies at the Woodrow Wilson International Center for Scholars, calls for significant changes in the U.S. government’s handling of nanotechnology risk research. The study, “Nanotechnology: A Research Strategy for Addressing Risk,” proposes a new framework for systematically exploring possible risks and argues that more money is required.

“Without such an approach,” Maynard said in a prepared statement, “significant knowledge gaps — which currently exist in all areas of nanotechnology risk assessment — will persist.”

According to Maynard’s analysis, as little as $11 million of the more than one billion dollars the U.S. government annually invests in nanotechnology research and development is devoted to highly relevant research into what is safe and what is not.

To fill the gap, Maynard argues that the federal government needs an overarching strategy and comprehensive set of research priorities. Initially, he suggests that these be aimed at identifying and measuring nanomaterials exposure and environmental release, evaluating nanomaterials toxicity, controlling the release of and exposure to engineered nanomaterials, and developing “best practices” for working safely with nanomaterials, and eventually at building capacity in predictive toxicology.

The report maintains that the effort should be led by federal agencies with a clear mandate for oversight and for research of environmental, health and safety (EHS) risk. Maynard estimates that oversight and EHS research agencies need a minimum budget of $50 million per year over the next two years to devote to highly relevant, targeted nanotechnology risk-based research.

This amount is in addition to a complementary investment by federal agencies and departments participating in the National Nanotechnology Initiative (NNI) on basic and applications-focused research that has the potential to help further understanding of nanotechnology risk and to aid in the development of improved research tools.

The report is available online at www.nanotechproject.org.